

Théa





A young company with a long history

30 years...
...and a 150-year history.

The Chibret family: 5 generations fully
dedicated to eye care



Paul Chibret
1844_1911

Ophthalmologist
Fondateur de la Société
Française d'Ophthalmologie



Henry Chibret
1876_1943

Pharmacist
Fondateur des
Laboratoires Chibret



Jean Chibret
1915_1989

Pharmacist
PDG des Laboratoires Chibret



Henri Chibret
1940

Pharmacist
Fondateur de Transphyto et des
Laboratoires Théa
Président du Directoire de Théa Holding



Jacques Chibret
1941_1989

MBA
Fondateur et PDG de Biophysic Medical



Jean-Frédéric Chibret
1975

MBA
Président du Groupe Théa

OUR ROOTS ARE SOLID AND WE PLAN TO STAY IN EYE CARE
FOR THE LONG TERM



Independent, family-owned, family-run

=> Consistency and continuity in our strategy in eye care

- Pharma company **100% dedicated** to ophthalmology
- **Long term vision** over immediate commercial gain
- **All profit is reinvested in Théa**: priority to **R&D** and **new territories but also education**
 - **Fast** decision-making process
 - **Stable ownership** and **management**
 - **Entrepreneurship** and **family** spirit
- A **unique proximity** (with teams, eyecare professionals, partners)

THE COMPANY IS GROWING BUT WE INSIST ON KEEPING THESE VALUES.



36

Affiliates & offices

EUROPE

Austria, Belgium, Bulgaria, Czech Republic, Denmark, Spain, Finland, France, Germany, Greece, Ireland, Italy, Monaco, Norway, Poland, Portugal, Romania, Slovakia, Sweden, Switzerland, The Netherlands, Turkey, United Kingdom, Ukraine

AMERICAS

Canada, USA
Chile, Mexico, Peru

AFRICA AND MIDDLE EAST

Algeria, Morocco, Tunisia
Kuwait, Saudi Arabia, UAE

36

Partners

EUROPE

Albania, Croatia, Cyprus, Estonia, Iceland, Latvia, Lithuania, Serbia, Slovenia

AMERICAS

Brazil

ASIA AND OCEANIA


Hong-Kong, Malaysia, Singapore, South Korea, Thailand

AFRICA AND MIDDLE EAST

Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Chad, Congo, Democratic Republic of Congo, Ivory Coast, Gabon, Guinea, Lebanon, Libya, Madagascar, Mali, Mauritania, Mauritius, Niger, Rwanda, Senegal, Togo


Turnover evolution (in € million)

80% of sales are made outside French territory



Théa Countries Ophthalmology Market

4,9 B € +5.6% - Mat July 2025 (w/o S01P - US- Canada - Perou-Middle East)






Top 10 Laboratories in Europe in € & MS%

(without S01P)

Last update December 2024





Théa's key facts and strengths


- ❑ **Europe: #1 in the non-retina ophthalmic market (in turnover)**
 - >600 reps, presenting a portfolio covering the needs of eyecare practitioners

- ❑ **US: in 2022, significant moves**
 - Acquisition of Akorn portfolio (Rx) on top of the launch of our OTC brand (Ivizia)
 - Dedicated sales team
 - Registration of our key European products through FDA - as Iyuzeh or Zolymbus
 - 60 people on the field



Théa's key facts and strengths

☐ A leader in Innovation



☐ Innovation

- 150 M€ yearly budget in Innovation in 2025 (around 15% of our turnover)

☐ R&D

- Formulation: our core historical expertise
- Late stage development: Phase 2 and 3 trials; registration procedures; pharmaco economics
- **30 innovations** have been developed by our in-house R&D in **30 years**.



30 innovations in 30 years

Théa R&D has generated over [30 innovations in 30 years](#), offering practitioners and their patients the [most modern range in eyecare](#), thanks to major therapeutic and technological advances.

We are [pioneers and leaders](#) in:

- Preservative free (90's)
- Eyelid hygiene (90's)
- Ocular nutrition (00's)
- Short duration antibiotherapy (10's)
- Intracameral antibiotics and mydriasis (10's)
- Trehalose-based dry eye treatment (10's)

We have brought [major advances](#) in:

- Glaucoma
- Dry eye
- Infection
- Antibiotics
- etc...



**Théa
Open
Innovation**

- Keeping our leadership by maintaining innovation in the **traditional therapeutic classes** (like Glaucoma and Ocular Surface)
- Entering into the **retina market and rares diseases** (as IRDs)





Our mission

**Identify, evaluate and develop
innovative ophthalmic solutions**

**In partnership with biotechs, startups
and medium-sized companies,
universities, ophthalmologists ...**





What we do

Through licensing agreements and/or equity investment, we aim to offer:

- **our expertise** for the developments in ophthalmology,
- **the funding** our future partners require to conduct proof of concept in humans.

We are looking for new products in development in ophthalmology, as soon they fill a **medical need**; as early as **in vivo proof of concept**, and as late as **Phase 3**





**Any
question ?**





We are one of the
most active
dealmakers in
ophthalmology
e.g. since 2021:

- **Curacle:** collaboration (ww except Asia) around CU06-RE, an orally administered treatment **for DME and wAMD**
- **Coave Therapeutics:** European collaboration on CTx-PDE6b, a novel gene therapy candidate **in retinitis pigmentosa**
- **Ripple Therapeutics:** collaboration on their **drug delivery system**
- **OliX Pharmaceuticals:** collaboration on OLX301A and OLX301D (ww except Asia). Those molecules are asi-RNAs which **target dry/wet AMD and wet AMD/subretinal fibrosis**, respectively.
- **Galimedix:** collaboration (ww except Asia) on GAL-101, early clinical small molecule **for dry AMD**
- **Vyluma:** collaboration on NVK-002 (Europe and some other territories). NVK-002 is a preservative-free, low-dose atropine chronic treatment developed **to slow down the progression of myopia**
- **Tsubota lab:** collaboration on TLM-003 (ww except Asia), a first-in-class treatment developed **to slow down the progression of myopia**
- **Link:** collaboration (ww except Asia) on a recombinant protein **in dry eye**
- Purchase of two IRD products : **Sepofarsen** indicated in LCA10 and **Ultevursen** indicated in USH2A retinitis pigmentosa
- **Kiora:** collaboration (ww except Asia) on KIO-301, molecular photoswitch, for the treatment of **retinitis pigmentosa**.
- **Inoculus:** development of a new product for our **Blepha range**